{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T10:08:30Z","timestamp":1785319710385,"version":"3.55.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The FABULOUS trial showed that fuzuloparib, with or without apatinib, significantly improved progression-free survival (PFS) in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer with germline breast cancer susceptibility genes 1 or 2 mutations compared to standard chemotherapy. The study assessed the cost-effectiveness of three treatment options from the perspective of China\u2019s healthcare system.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A partitioned survival model was created to evaluate cost-effectiveness. The model incorporated direct medical costs, with drug prices derived from local charges and other costs as well as utility data from published literature. Both costs and utility values were discounted at an annual rate of 4.5%. The incremental cost-effectiveness ratio (ICER) served as the primary outcome. The treatment regimen was determined to be cost-effective if the ICER was below the willingness-to-pay (WTP) threshold of $26,083\/quality-adjusted life year (QALY). One-way sensitivity, probabilistic sensitivity and scenario analyses were also conducted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The ICERs for fuzuloparib versus chemotherapy, fuzuloparib versus fuzuloparib-apatinib, and fuzuloparib-apatinib versus chemotherapy were calculated as $141,912.74\/QALY, $285,196.26\/QALY, and $90,074.03\/QALY, respectively. Accordingly, neither fuzuloparib plus apatinib nor fuzuloparib monotherapy was found to be cost-effective compared with standard chemotherapy at the WTP threshold of $26,083\/QALY. Moreover, fuzuloparib monotherapy was not cost-effective compared with fuzuloparib plus apatinib. Sensitivity and scenario analyses affirmed the robustness of the model. One-way sensitivity analysis showed that utility for PFS, utility for progressive disease, and costs associated with subsequent treatment exerted the most substantial influence on the outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Although fuzuloparib, with or without apatinib, has shown substantial clinical benefits, it has not proven to be cost-effective when compared to standard chemotherapy. Further global multicenter or population-specific clinical trials involving breast cancer patients are necessary to enhance the understanding of the application scope and cost-effectiveness of fuzuloparib.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1864488","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T09:48:03Z","timestamp":1782985683000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Cost-effectiveness of fuzuloparib, with or without apatinib, for BRCA mutation HER2-negative metastatic breast cancer in China"],"prefix":"10.3389","volume":"17","author":[{"given":"Yingzhou","family":"Fu","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Hunan Cancer Hospital","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengxiong","family":"Li","sequence":"additional","affiliation":[{"name":"School of Medical Informatics and Engineering, Xuzhou Medical University","place":["Xuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Hunan Cancer Hospital","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojuan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Hunan Cancer Hospital","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuojuan","family":"Xiang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Hunan Cancer Hospital","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"11597","DOI":"10.1158\/0008-5472.CAN-05-2119","article-title":"Hypoxia-induced down-regulation of BRCA1 expression by E2Fs","volume":"65","author":"Bindra","year":"2005","journal-title":"Cancer Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"B3","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1080\/13696998.2023.2182051","article-title":"Cost-effectiveness of ribociclib versus palbociclib in combination with an aromatase inhibitor as first-line treatment of postmenopausal women with HR+\/HER2-advanced breast cancer: analysis based on final OS results of MONALEESA-2 and PALOMA-2","volume":"26","author":"Cameron","year":"2023","journal-title":"J. Med. Econ."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1333487","DOI":"10.3389\/fpubh.2024.1333487","article-title":"The cost-effectiveness of Iruplinalkib versus alectinib in anaplastic lymphoma kinase-positive crizotinib-resistant advanced non-small-cell lung cancer patients in China","volume":"12","author":"Dai","year":"2024","journal-title":"Front. Public Health"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/S1470-2045(20)30447-2","article-title":"Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"21","author":"Di\u00e9ras","year":"2020","journal-title":"Lancet Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"17588359251379708","DOI":"10.1177\/17588359251379708","article-title":"Cost-effectiveness analysis of belzutifan versus everolimus for previously treated advanced clear cell renal cell carcinoma in the United States and China","volume":"17","author":"Ding","year":"2025","journal-title":"Ther. Adv. Med. Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med. Res. Methodol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jncc.2024.01.006","article-title":"Cancer incidence and mortality in China, 2022","volume":"4","author":"Han","year":"2024","journal-title":"J. Natl. Cancer Cent."},{"key":"B9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","article-title":"CHEERS 2022 ISPOR good research practices task force. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"25","author":"Husereau","year":"2022","journal-title":"Value Health"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S1470-2045(25)00523-6","article-title":"Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1\/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial","volume":"26","author":"Li","year":"","journal-title":"Lancet Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13045-025-01660-y","article-title":"Global status and attributable risk factors of breast, cervical, ovarian, and uterine cancers from 1990 to 2021","volume":"18","author":"Li","year":"","journal-title":"J. Hematol. Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.neo.2014.04.003","article-title":"VEGFR3 inhibition chemosensitizes ovarian cancer stemlike cells through down-regulation of BRCA1 and BRCA2","volume":"16","author":"Lim","year":"2014","journal-title":"Neoplasia"},{"key":"B14","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"987337","DOI":"10.3389\/fphar.2022.987337","article-title":"Cost-effectiveness of fuzuloparib compared to routine surveillance, niraparib and olaparib for maintenance treatment of patients with germline BRCA1\/2 mutation and platinum-sensitive recurrent ovarian carcinoma in China","volume":"13","author":"Nie","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"13935","DOI":"10.1038\/s41598-024-64343-7","article-title":"Cost-effectiveness of talazoparib for patients with germline BRCA1\/2 mutated HER2-negative advanced breast cancer in China and the US","volume":"14","author":"Pan","year":"2024","journal-title":"Sci. Rep."},{"key":"B17","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41586-024-07217-2","article-title":"Transcription-replication conflicts underlie sensitivity to PARP inhibitors","volume":"628","author":"Petropoulos","year":"2024","journal-title":"Nature"},{"key":"B18","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1001\/jamaoncol.2020.0007","article-title":"Association of germline variant status with therapy response in high-risk early-stage breast cancer: a secondary analysis of the GeparOcto randomized clinical trial","volume":"6","author":"Pohl-Rescigno","year":"2020","journal-title":"JAMA Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.21037\/tcr-22-2799","article-title":"Epidemiology and clinicopathologic features of breast cancer in China and the United States","volume":"12","author":"Qian","year":"2023","journal-title":"Transl. Cancer Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S2468-1253(21)00109-6","article-title":"Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"6","author":"Qin","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s40259-023-00586-6","article-title":"Serplulimab plus chemotherapy vs chemotherapy for treatment of US and Chinese patients with extensive-stage small-cell lung cancer: a cost-effectiveness analysis to inform drug pricing","volume":"37","author":"Shao","year":"","journal-title":"BioDrugs"},{"key":"B24","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s41669-023-00391-5","article-title":"Impact of extrapolation model choices on the structural uncertainty in economic evaluations for cancer immunotherapy: a case study of checkmate 067","volume":"7","author":"Shao","year":"","journal-title":"Pharmacoecon. Open"},{"key":"B25","doi-asserted-by":"publisher","first-page":"104550","DOI":"10.1016\/j.breast.2025.104550","article-title":"Cost-effectiveness of sacituzumab tirumotecan versus chemotherapy for patients with metastatic triple-negative breast cancer in China","volume":"83","author":"Shu","year":"2025","journal-title":"Breast"},{"key":"B26","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.ygyno.2015.02.017","article-title":"Two decades beyond BRCA1\/2: homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy","volume":"137","author":"Walsh","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s43556-025-00385-1","article-title":"PARPs and PARP inhibitors: molecular mechanisms and clinical applications","volume":"6","author":"Wang","year":"2025","journal-title":"Mol. Biomed."},{"key":"B28","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1038\/s12276-026-01673-8","article-title":"PARP inhibitors and breast cancer: from therapeutic breakthrough to resistance challenge","volume":"58","author":"Wang","year":"2026","journal-title":"Exp. Mol. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1186\/s12913-024-11514-x","article-title":"Economic burden of patients with leading cancers in China: a cost-of-illness study","volume":"24","author":"Wu","year":"2024","journal-title":"BMC Health Serv. Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e70042","DOI":"10.3322\/caac.70042","article-title":"Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): a multicenter, randomized, double-blind, placebo-controlled phase 3 trial","volume":"76","author":"Wu","year":"2026","journal-title":"CA Cancer J. Clin."},{"key":"B31","doi-asserted-by":"publisher","first-page":"21","DOI":"10.7664\/CHE20160305","article-title":"A study on the measurement of health utility values of breast cancer patients","volume":"35","author":"Xu","year":"2016","journal-title":"China Health Econ."},{"key":"B35","doi-asserted-by":"publisher","first-page":"e013070","DOI":"10.1136\/bmjgh-2023-013070","article-title":"Establishing cost-effectiveness threshold in China: a community survey of willingness to pay for a healthy life year","volume":"9","author":"Xu","year":"2024","journal-title":"BMJ Glob. Health"},{"key":"B32","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12962-025-00617-9","article-title":"Cost-utility analysis of olaparib assisted targeted therapy for BRCA mutation HER2-negative early breast cancer in China and in the United States","volume":"23","author":"Xu","year":"2025","journal-title":"Cost. Eff. Resour. Alloc."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.3760\/cma.j.cn112338-20240129-00048","article-title":"Disease burden and economic burden of breast cancer in females in China: a synthesis analysis","volume":"45","author":"Zhou","year":"2024","journal-title":"Zhonghua Liu Xing Bing Xue Za Zhi"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1068463","DOI":"10.3389\/fonc.2023.1068463","article-title":"Cost-effectiveness of palbociclib plus fulvestrant as second-line therapy of women with HR+\/HER2-advanced breast cancer - a Chinese healthcare system perspective","volume":"13","author":"Zhu","year":"2023","journal-title":"Front. Oncol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1864488\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T09:48:06Z","timestamp":1782985686000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1864488\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":35,"alternative-id":["10.3389\/fphar.2026.1864488"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1864488","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]},"article-number":"1864488"}}